Angiogenesis can be reduced without significant reduction of tumor growth

Anticancer Research

Volumn 27, Issue 6 B, 2007, Pages 3883-3889

  Svensson, Åsa ^a   Bäckman, Ulrika ^a   Fuchs, Dieter ^a   Christofferson, Rolf ^a   Azarbayjani, Faranak ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Angiogenesis inhibition; Angiogenesis stimulators; Angiogenesis threshold; Mice; Neuroblastoma; TNP 470

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FUMAGILLOL CHLOROACETYLCARBAMATE; SCATTER FACTOR; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANIMALS; CATTLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLOHEXANES; ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; SESQUITERPENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 37549018042     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
2. Folkman J, Browder T and Palmblad J: Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 86: 23-33, 2001.
3. Antoine N, Greimers R, De Roanne C, Kusaka M, Heinen E, Simar LJ and Castronovo V: AGM-1470, a potent angiogenesis inhibitor, prevents the entry of normal but not transformed endothelial cells into the G1 phase of the cell cycle. Cancer Res 54: 2073-2076, 1994.
4. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H and Folkman J: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555-557, 1990.
5. Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D and Folkman J: Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun 174: 1070-1076, 1991.
6. Kusaka M, Sudo K, Matsutani E, Kozai Y, Marui S, Fujita T, Ingber D and Folkman J: Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 69: 212-216, 1994.
7. Berthold F and Hero B: Neuroblastoma: current drug therapy recommendations as part of the total treatment approach. Drugs 59: 1261-1277, 2000.
8. Meitar D, Crawford SE, Rademaker AW and Cohn SL: Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 14: 405-414, 1996.
9. Rossler J, Breit S, Havers W and Schweigerer L: Vascular endothelial growth factor expression in human neuroblastoma: up-regulation by hypoxia. Int J Cancer 81: 113-117, 1999.
10. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM and Himelstein BP: High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 6: 1900-1908, 2000.
11. Nagabuchi E, VanderKolk WE, Une Y and Ziegler MM: TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. J Pediatr Surg 32: 287-293, 1997.
12. Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H and Maris JM: The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res 7: 977-984, 2001.
13. Shusterman S, Grupp SA and Maris JM: Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470. Med Pediatr Oncol 35: 673-676, 2000.
14. Wassberg E, Pahlman S, Westlin JE and Christofferson R: The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats. Pediatr Res 41: 327-333, 1997.
15. Biedler JL, Roffler-Tarlov S, Schachner M and Freedman LS: Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 38: 3751-3757, 1978.
16. Qi JH, Matsumoto T, Huang K, Olausson K, Christofferson R and Claesson-Welsh L: Phosphoinositide 3 kinase is critical for survival, mitogenesis and migration but not for differentiation of endothelial cells. Angiogenesis 3: 371-380, 1999.
17. Larsson R, Kristensen J, Sandberg C and Nygren P: Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 50: 177-185, 1992.
18. Folkman J: Tumor angiogenesis. In: Accomplishments in Cancer Research. Wells SJ and Sharp P (eds.) Lippincott Williams and Wilkins, New York, pp. 32-44, 1998.
19. Satchi-Fainaro R, Puder M, Davies JW, Tran HT, Sampson DA, Greene AK, Corfas G and Folkman J: Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 10: 255-261, 2004.
20. Wassberg E, Hedborg F, Skoldenberg E, Stridsberg M and Christofferson R: Inhibition of angiogenesis induces chromaffin differentiation and apoptosis in neuroblastoma. Am J Pathol 154: 395-403, 1999.
21. Liu S, Widom J, Kemp CW, Crews CM and Clardy J: Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 282: 1324-1327, 1998.
22. Beecken WD, Fernandez A, Joussen AM, Achilles EG, Flynn E, Lo KM, Gillies SD, Javaherian K, Folkman J and Shing Y: Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. J Natl Cancer Inst 93: 382-387, 2001.
23. Beecken WD, Fernandez A, Panigrahy D, Achilles EG, Kisker O, Flynn E, Joussen AM, Folkman J and Shing Y: Efficacy of antiangiogenic therapy with TNP-470 in superficial and invasive bladder cancer models in mice. Urology 56: 521-526, 2000.
24. Satchi-Fainaro R, Mamluk R, Wang L, Short SM, Nagy JA, Feng D, Dvorak AM, Dvorak HF, Puder M, Mukhopadhyay D and Folkman J: Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 7: 251-261, 2005.
25. Inoue K, Chikazawa M, Fukata S, Yoshikawa C and Shuin T: Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder. Clin Cancer Res 8: 2389-2398, 2002.
26. Helmlinger G, Yuan F, Dellian M and Jain RK: Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3: 177-182, 1997.
27. Byrne AM, Bouchier-Hayes DJ and Harmey JH: Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9: 777-794, 2005.
28. Svensson A, Backman U, Jonsson E, Larsson R and Christofferson R: CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs. Pediatr Res 51: 607-611, 2002.
29. Jia L, Zhang MH, Yuan SZ and Huang WG: Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice. World J Gastroenterol 11: 447-450, 2005.
30. Kato T, Sato K, Kakinuma H and Matsuda Y: Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagiUol (TNP-470) and cytotoxic agents in mice. Cancer Res 54: 5143-5147, 1994.
31. Bhargava P, Marshall JL, Rizvi N, Dahut W, Yoe J, Figuera M, Phipps K, Ong VS, Kato A and Hawkins MJ: A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 5: 1989-1995, 1999.
32. Herbst RS, Madden TL, Tran HT, Blumenschein GR Jr, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA Jr, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T and Hong WK: Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol 20: 4440-4447, 2002.
33. Tran HT, Blumenschein GR Jr, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M and Herbst RS: Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 54: 308-314, 2004.
34. Matsumura Y and Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 6387-6392, 1986.
35. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T and Maeda H: Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 89: 307-314, 1998.
36. Wang J, Sheppard GS, Lou P, Kawai M, BaMaung N, Erickson SA, Tucker-Garcia L, Park C, Bouska J, Wang YC, Frost D, Tapang P, Albert DH, Morgan SJ, Morowitz M, Shusterman S, Maris JM, Lesniewski R and Henkin J: Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res 63: 7861-7869, 2003.
37. Morowitz MJ, Barr R, Wang Q, King R, Rhodin N, Pawel B, Zhao H, Erickson SA, Sheppard GS, Wang J, Maris JM and Shusterman S: Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models. Clin Cancer Res 11: 2680-2685, 2005.
38. Bergers G, Javaherian K, Lo KM, Folkman J and Hanahan D: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284: 808-812, 1999.
39. Katzenstein HM, Rademaker AW, Senger C, Salwen HR, Nguyen NN, Thorner PS, Litsas L and Cohn SL: Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin Cancer Res 5: 4273-4278, 1999.
40. Katzenstein HM, Salwen HR, Nguyen NN, Meitar D and Cohn SL: Antiangiogenic therapy inhibits human neuroblastoma growth. Med Pediatr Oncol 36: 190-193, 2001.
41. Cernaianu G, Frank S, Erbstosser K, Leonhardt S, Cross M, McIvor Z, Scholz G, Dansranjavin T, Celik I, Tannapfel A, Wittekind C, Troebs RB, Rothe K, Bennek J, Hauss J and Witzigmann H: TNP-470 fails to block the onset of angiogenesis and early tumor establishment in an intravital minimal disease model. Int J Colorectal Dis 21: 143-154, 2006.